In addition to showing the phenotype in cancer-derived cells, we used siRNA knockdown of MYC and MAPK inhibitor treatments as alternative approaches to validate that depletion of oncogenes and inhibition of their signaling reverses these effects on interferon and ISG expression. The gene discussed is MYC; the disease is cancer.